Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
AI-based staging, causal hypothesis and progression of subjects at risk of Alzheimer’s disease: a multicenter study
1
Zitationen
16
Autoren
2025
Jahr
Abstract
Introduction In 2024, 11 European scientific societies/organizations and one patient advocacy association have defined a patient-centered biomarker-based diagnostic workflow for memory clinics evaluating neurocognitive disorders. Methods We tested the performance of an artificial intelligence (AI) tool applied to neuropsychological and magnetic resonance imaging (MRI) assessment for staging and causal hypothesis, which are the two recommended workflow steps guiding the next one recommending optimal biomarkers to be used for a biological diagnosis of neurocognitive disorders, according to intersocietal recommendations. Moreover, we assessed the AI performance in predicting the progression to Alzheimer’s disease (AD)-dementia. Results For the three-class classification of staging (n patients = 426), the inter-rater AI-humans agreement was substantial for both healthy subjects/subjective cognitive impairment/worried-well vs. all the remaining groups (rest) (Cohen’s κ = 0.81) and mild cognitive impairment/mild dementia vs. rest κ = 0.70) classification, almost perfect for moderate/severe dementia vs. rest κ =0.90) classification. For the three-class classification of causal hypotheses ( n = 112), the AI performance vs. biomarker-based diagnosis was: positive predictive value 91% [95% CI: 84–96%]; negative predictive value 100%, and accuracy 91% [84–96%]. For the binary classification of progression or not progression to AD-dementia at 24-month, with clinical conversion as a reference standard ( n = 341), the AI performance was: sensitivity 89% [84–94%], specificity 82% [77–87%]; accuracy 85% [81–89%]; and area under the receiver operating characteristic curve 83% [79–87%]. Discussion The AI tool showed high agreement with human assessment for staging, high accuracy with biomarkers for causal hypotheses of neurocognitive disorders and predicted progression to AD at 24-month with 89% sensitivity and 82% specificity.
Ähnliche Arbeiten
The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research
1989 · 34.309 Zit.
Clinical diagnosis of Alzheimer's disease
1984 · 27.959 Zit.
The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment
2005 · 25.113 Zit.
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
2013 · 20.659 Zit.
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
2011 · 18.715 Zit.
Autoren
Institutionen
- Istituto Universitario di Studi Superiori di Pavia(IT)
- Centro Diagnostico Italiano(IT)
- IRCCS Policlinico San Donato(IT)
- University of Milan(IT)
- Centro Neurolesi Bonino Pulejo(IT)
- Istituti Clinici Scientifici Maugeri(IT)
- Lega Italiana per la Lotta ai Tumori(IT)
- University of Verona(IT)
- University of Milano-Bicocca(IT)
- CE Technologies (United Kingdom)(GB)